Tuesday, 22 September 2020

SPARC Licenses Commercialization Rights of ElepsiaTM XR to Tripoint Therapeutics

Sun Pharma Advanced Research Company Ltd announced the grant of an exclusive license to Tripoint Therapeutics LLC, USA (Tripoint) to commercialize ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg tablets in the USA.



source https://www.pharmatutor.org/pharma-news/2020/sparc-licenses-commercialization-rights-of-elepsiatm-xr-to-tripoint-therapeutics

No comments:

Post a Comment

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...